Skip to content
DraconiticResearch
Search Sources API
182,544 studies31 sourcesUpdated 23 min ago
Peer-reviewedCC BY 4.0Frontiers in Pharmacology

Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex

  • Qingmei Li1
  • Shuming Liu2
  • Huiling Chen3,4
  • Guangda Liang3,5
  • Zhouyi Song3,5
  • Yanfang Liu3,5
  • Xingfeng Liu3,5
  • Bangyong Qin4
5 affiliations
  1. 1Department of Anesthesiology, The Affiliated Hospital of Zunyi Medical University
  2. 2Department of Anesthesiology, The Affiliated Stomatological Hospital of Zunyi Medical University
  3. 3Guizhou Key Laboratory of Anesthesia and Organ Protection of Ministry of Education (In Cultivation), Zunyi Medical University
  4. 4Department of Pain Medicine, The Affiliated Hospital of Zunyi Medical University
  5. 5Guizhou Key Laboratory of Brain Science, Zunyi Medical University
Read full textPDFDOICite

Abstract

Objective: The molecular mechanisms driving esketamine (ESK) efficacy in the pain-depression dyad (PDD) remain incompletely understood. This study investigated the effects of a sub-anesthetic ESK regimen on cortical expression profiles and exploratory signaling markers within the anterior cingulate cortex (ACC).

Methods: Male Sprague-Dawley rats were randomized into Sham, PDD, and PDD + ESK groups. The PDD model, established via chronic constriction injury (CCI), was validated using a behavioral test battery tracking mechanical allodynia and depression-like phenotypes. On day 21 post-surgery, PDD + ESK rats received a single esketamine injection (15 mg/kg, i.p.). Multi-regional c-Fos expression mapping across the PFC, HPC, and ACC identified the primary responsive structure, followed by dual immunofluorescence for cellular phenotyping. Finally, ACC excitatory neuronal calcium dynamics, exploratory transcriptomic profiles, and Wnt4-associated molecular alterations (including GSK3β and mTOR phosphorylation alongside synaptic markers) were evaluated using fiber photometry, RNA sequencing, and Western blotting.

Results: ESK alleviated pain hypersensitivity, behavioral despair, and anhedonia in PDD rats. Regional c-Fos profiling identified the ACC as the primary reactive locus, with activation localized predominantly to CaMKIIα-positive neurons. Fiber photometry confirmed that ESK attenuated functional hyperactivation in these ACC excitatory neurons. Exploratory transcriptomic profiling (unadjusted P < 0.05) revealed candidate altered transcripts, identifying Wnt4 as an exploratory molecular marker for further investigation. Subsequent orthogonal protein validations demonstrated that ESK modulated Wnt4 expression alongside concomitant alterations in GSK3β and mTOR phosphorylation, parallel with the attenuation of pathologically elevated synaptic protein markers and a restorative trend in synaptic ultrastructure.

Conclusion: A single sub-anesthetic ESK dose effectively alleviates PDD behavioral phenotypes in rats. This therapeutic efficacy is associated with Wnt4-related molecular adjustments coupled with putative downstream GSK3β-mTOR signaling alterations within the ACC CaMKIIα-positive neurons, providing exploratory transcriptomic and molecular insights into cortical adaptations in pain-related affective disorders.

Related

  1. Electroacupuncture Alleviates Comorbid Depression‐Like Behaviors and Dyspepsia‐Like Symptoms in Rats Accompanied by Alterations in Hippocampal Neuroinflammation and Gut Microbiota
    Tianlang Wang, Yifan Feng, Xihan Wang +5
    Brain and behaviorPeer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ
  2. Exploratory mRNA and microRNA profiling identifies transcriptomic alterations in the PIK3CA-related overgrowth spectrum
    Tadashi Shiohama, Tadashi Shiohama, Mami Uegami +9
    Frontiers in GeneticsPeer-reviewedCC BYFull textSurgery & anaesthesiaDOAJ
  3. Esketamine for Treatment-Resistant Depression
    Ioana Cristea, Martin Plöderl, Florian Naudet
    JAMA PsychiatryPeer-reviewedCC BY-NC 4.0Full textGeneral biologyPsychiatry & mental healthHAL
  4. Baseline Response Criterion and Changes in Emotional Bias as Markers of Esketamine Response in Treatment-Resistant Depression
    C. Muh, P. Favre, I. K. Lutkenherm +3
    medRxivPreprintCC BYFull textPsychiatry & mental healthmedRxiv
  5. Oral Esketamine Maintenance Treatment for Treatment‐Resistant Depression: Clinical Outcomes During an Off‐Label Treatment Program
    Sanne Y. Smith-Apeldoorn, Jolien K. E. Veraart, Jan Spijker +3
    Depression and AnxietyPeer-reviewedCC BY 4.0Full textPharmacology & toxicologyPMC

Cite

BibTeXRIS
BibTeX
@article{li2026esketamine,
  title = {{Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex}},
  author = {Qingmei Li and Shuming Liu and Huiling Chen and Guangda Liang and Zhouyi Song and Yanfang Liu and Xingfeng Liu and Bangyong Qin},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  month = oct,
  doi = {10.3389/fphar.2026.1873924},
  url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1873924/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Esketamine alleviates the pain-depression dyad: insights from exploratory transcriptomic profiling and Wnt4-associated molecular alterations within the anterior cingulate cortex
AU  - Qingmei Li
AU  - Shuming Liu
AU  - Huiling Chen
AU  - Guangda Liang
AU  - Zhouyi Song
AU  - Yanfang Liu
AU  - Xingfeng Liu
AU  - Bangyong Qin
PY  - 2026
DA  - 2026/10/16
JO  - Frontiers in Pharmacology
DO  - 10.3389/fphar.2026.1873924
UR  - https://www.frontiersin.org/articles/10.3389/fphar.2026.1873924/full
AB  - Objective: The molecular mechanisms driving esketamine (ESK) efficacy in the pain-depression dyad (PDD) remain incompletely understood. This study investigated the effects of a sub-anesthetic ESK regimen on cortical expression profiles and exploratory signaling markers within the anterior cingulate cortex (ACC).  Methods: Male Sprague-Dawley rats were randomized into Sham, PDD, and PDD + ESK groups. The PDD model, established via chronic constriction injury (CCI), was validated using a behavioral test battery tracking mechanical allodynia and depression-like phenotypes. On day 21 post-surgery, PDD + ESK rats received a single esketamine injection (15 mg/kg, i.p.). Multi-regional c-Fos expression mapping across the PFC, HPC, and ACC identified the primary responsive structure, followed by dual immunofluorescence for cellular phenotyping. Finally, ACC excitatory neuronal calcium dynamics, exploratory transcriptomic profiles, and Wnt4-associated molecular alterations (including GSK3β and mTOR phosphorylation alongside synaptic markers) were evaluated using fiber photometry, RNA sequencing, and Western blotting.  Results: ESK alleviated pain hypersensitivity, behavioral despair, and anhedonia in PDD rats. Regional c-Fos profiling identified the ACC as the primary reactive locus, with activation localized predominantly to CaMKIIα-positive neurons. Fiber photometry confirmed that ESK attenuated functional hyperactivation in these ACC excitatory neurons. Exploratory transcriptomic profiling (unadjusted P < 0.05) revealed candidate altered transcripts, identifying Wnt4 as an exploratory molecular marker for further investigation. Subsequent orthogonal protein validations demonstrated that ESK modulated Wnt4 expression alongside concomitant alterations in GSK3β and mTOR phosphorylation, parallel with the attenuation of pathologically elevated synaptic protein markers and a restorative trend in synaptic ultrastructure.  Conclusion: A single sub-anesthetic ESK dose effectively alleviates PDD behavioral phenotypes in rats. This therapeutic efficacy is associated with Wnt4-related molecular adjustments coupled with putative downstream GSK3β-mTOR signaling alterations within the ACC CaMKIIα-positive neurons, providing exploratory transcriptomic and molecular insights into cortical adaptations in pain-related affective disorders.
SN  - 1663-9812
ER  -